[go: up one dir, main page]

NO20020151L - Veksthormonformuleringer - Google Patents

Veksthormonformuleringer

Info

Publication number
NO20020151L
NO20020151L NO20020151A NO20020151A NO20020151L NO 20020151 L NO20020151 L NO 20020151L NO 20020151 A NO20020151 A NO 20020151A NO 20020151 A NO20020151 A NO 20020151A NO 20020151 L NO20020151 L NO 20020151L
Authority
NO
Norway
Prior art keywords
growth hormone
result
temperatures
formulation
mannitol
Prior art date
Application number
NO20020151A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020151D0 (no
Inventor
Bernhard Siebold
John Stevens
Original Assignee
Grandis Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20020151(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916252.1A external-priority patent/GB9916252D0/en
Priority claimed from GBGB9918902.9A external-priority patent/GB9918902D0/en
Application filed by Grandis Biotech Gmbh filed Critical Grandis Biotech Gmbh
Publication of NO20020151D0 publication Critical patent/NO20020151D0/no
Publication of NO20020151L publication Critical patent/NO20020151L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
NO20020151A 1999-07-12 2002-01-11 Veksthormonformuleringer NO20020151L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9916252.1A GB9916252D0 (en) 1999-07-12 1999-07-12 Growth hormone formulation
GBGB9918902.9A GB9918902D0 (en) 1999-08-12 1999-08-12 Growth hormone formulation
PCT/GB2000/002664 WO2001003741A1 (fr) 1999-07-12 2000-07-11 Preparations d'hormones de croissance

Publications (2)

Publication Number Publication Date
NO20020151D0 NO20020151D0 (no) 2002-01-11
NO20020151L true NO20020151L (no) 2002-03-12

Family

ID=26315757

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020151A NO20020151L (no) 1999-07-12 2002-01-11 Veksthormonformuleringer

Country Status (25)

Country Link
US (1) US20060029635A1 (fr)
EP (1) EP1194170B1 (fr)
JP (3) JP2003504346A (fr)
KR (1) KR20020031388A (fr)
CN (1) CN1360506A (fr)
AR (1) AR024728A1 (fr)
AT (1) ATE386501T1 (fr)
AU (1) AU775107C (fr)
BR (1) BR0013162A (fr)
CA (1) CA2378949C (fr)
CZ (1) CZ200260A3 (fr)
DE (1) DE60038118T2 (fr)
ES (1) ES2300268T3 (fr)
HK (1) HK1046358A1 (fr)
HU (1) HUP0202189A3 (fr)
IL (2) IL147253A0 (fr)
MX (1) MXPA02000404A (fr)
NO (1) NO20020151L (fr)
NZ (1) NZ516507A (fr)
PL (1) PL353238A1 (fr)
SI (1) SI1194170T1 (fr)
SK (1) SK252002A3 (fr)
TR (1) TR200200034T2 (fr)
TW (1) TWI247608B (fr)
WO (1) WO2001003741A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
MXPA05000412A (es) * 2002-07-09 2005-07-22 Sandoz Ag Formulacioneks liquidas con una alta concentracion de hormona de crecimiento humana (hgh) que comprenden glicina.
EP1603588A2 (fr) * 2003-03-18 2005-12-14 Ares Trading S.A. Stabilisation d'hormones de croissance en solution
WO2005027960A1 (fr) * 2003-09-25 2005-03-31 Cangene Corporation Formulation liquide de l'hormone de croissance humaine contenant du polyethylene glycol
BRPI0418115A (pt) 2003-12-23 2007-04-17 Pharmacia Corp formulação lìquida estável de hormÈnio de crescimento
EP1740213B9 (fr) * 2004-04-07 2012-06-13 Ares Trading S.A. Formulation liquide avec une hormone de croissance
US8293532B2 (en) 2009-03-26 2012-10-23 Dow AgroSciences, L.L.C. Method and apparatus for tissue transfer
RU2558821C2 (ru) * 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
JP6363949B2 (ja) 2011-07-25 2018-07-25 サンド アクチェンゲゼルシャフト 少なくとも中性塩および生物薬学的タンパク質を含む、水性製剤
US20130288968A1 (en) * 2012-04-30 2013-10-31 Sun Pharmaceutical Industries Ltd. Leuprolide injection
JP6001401B2 (ja) * 2012-09-28 2016-10-05 ユニ・チャーム株式会社 ウェットティッシュ用薬液及びウェットティッシュ
US10647819B2 (en) 2015-12-10 2020-05-12 Mitsubishi Gas Chemical Company, Inc. Photocurable composition and optical material
WO2018142514A1 (fr) * 2017-02-01 2018-08-09 協和発酵キリン株式会社 Composition pharmaceutique liquide contenant de la darbépoétine
WO2020004368A1 (fr) * 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 Formulation liquide aqueuse contenant des protéines
CA3196481A1 (fr) * 2020-11-16 2022-05-19 W. L. Gore & Associates, Inc. Formulations, procedes et dispositifs d'injection multi-dose pre-remplis sans point de trouble
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
AU6073386A (en) * 1985-07-30 1987-02-05 International Minerals & Chemical Corporation Stabilization of growth promoting hormones
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
CA1331133C (fr) * 1988-03-01 1994-08-02 Michael Jon Pikal Formulations pharmaceutiques d'hormone de croissance humaine
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
DK0549694T3 (da) * 1990-09-21 1995-10-16 Novo Nordisk As Adaptertop
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DE69334134T2 (de) * 1992-07-31 2007-12-20 Genentech, Inc., South San Francisco Wässrige Formulierung enthaltend Menschliches Wachstumshormon
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
JP2000504723A (ja) * 1996-02-13 2000-04-18 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ―２阻害剤および５―リポキシゲナーゼ阻害剤投与の免疫抑制効果
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物

Also Published As

Publication number Publication date
AU775107C (en) 2005-02-24
CN1360506A (zh) 2002-07-24
CA2378949A1 (fr) 2001-01-18
CZ200260A3 (cs) 2002-04-17
DE60038118D1 (de) 2008-04-03
CA2378949C (fr) 2015-03-31
IL147253A0 (en) 2002-08-14
US20060029635A1 (en) 2006-02-09
NO20020151D0 (no) 2002-01-11
EP1194170A1 (fr) 2002-04-10
SK252002A3 (en) 2002-06-04
ATE386501T1 (de) 2008-03-15
JP2012051891A (ja) 2012-03-15
AU5997500A (en) 2001-01-30
JP2003504346A (ja) 2003-02-04
AU775107B2 (en) 2004-07-15
KR20020031388A (ko) 2002-05-01
HUP0202189A3 (en) 2003-07-28
AR024728A1 (es) 2002-10-23
TR200200034T2 (tr) 2002-05-21
IL147253A (en) 2007-07-24
SI1194170T1 (sl) 2008-10-31
DE60038118T2 (de) 2009-03-05
BR0013162A (pt) 2002-05-28
HUP0202189A2 (en) 2002-10-28
JP5941496B2 (ja) 2016-06-29
JP2014208656A (ja) 2014-11-06
WO2001003741B1 (fr) 2001-04-19
EP1194170B1 (fr) 2008-02-20
PL353238A1 (en) 2003-11-03
HK1046358A1 (zh) 2003-01-10
ES2300268T3 (es) 2008-06-16
TWI247608B (en) 2006-01-21
WO2001003741A1 (fr) 2001-01-18
MXPA02000404A (es) 2004-05-21
NZ516507A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
NO20020151L (no) Veksthormonformuleringer
CN108107210A (zh) 一种髓过氧化物酶冻干校准品的制备方法及冻干保护液
JP2019533442A5 (fr)
JP2019532665A (ja) 細菌を保存するための方法および組成物
Bootwalla et al. Development of diluents for domestic fowl semen
CN105733947A (zh) 一种茶树菇菌种低温保藏及解冻方法
US20030186212A1 (en) Semen extender composition and methods for manufacturing and using
JP3364680B2 (ja) 豚精液保存用希釈液および豚精液の希釈保存法
CN101642572A (zh) 海洋微生物溶菌酶保护冻干粉的制造方法
BRPI0509321B1 (pt) Processos de preparação na panificação de um melhorador líquido e de uma massa para produto cozido de panificação, melhorador e uso de um melhorador
CN101019570B (zh) 哈密瓜专用保鲜剂
CN105925483A (zh) 一种真姬菇菌种低温保藏及解冻方法
WO2023072137A1 (fr) Stabilisateur de protéine, kit de test de réactif et procédé de protection de protéine
US6579707B2 (en) Stabilization of enzymes during freezing
CN110065688A (zh) 一种猪粪源生物肥料的生产包装方法
CN108077244A (zh) 一种长效猪精液稀释粉
CN116549652A (zh) 一种冻干保护剂、冻干试剂及其制备方法
KR102123805B1 (ko) 클로렐라의 냉동 보관 방법
Williamson Selective media in the enumeration of bacteria in pitching yeasts
CN111742980A (zh) 一种生物膜抑制剂及其制备方法和应用
CN107174663A (zh) 疫苗冻干保护剂
US7022649B2 (en) Composition for inoculating legumes and method therefor
JP3937019B2 (ja) 微生物保存用分散媒及び微生物保存用容器
CN111592993B (zh) 一种解淀粉芽孢杆菌菌剂保藏剂
CN101775380B (zh) 甜菜碱作为丙氨酸氨基转移酶稳定剂的应用及丙氨酸氨基转移酶校准品组合物

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application